MapLight Therapeutics was assigned a Hold rating ahead of its Phase 2 ZEPHYR readout for ML-007C-MA in schizophrenia expected in mid-August. ML-007C-MA is positioned as a best-in-class challenger to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results